Lowest Price Guaranteed From USD 5,899
Published
January 2023
Slides
160
View Count
7239
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
In the past few years, messenger ribonucleic acid (mRNA) has emerged as one of the key therapeutic modalities in the modern healthcare industry. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as oncological disorders, infectious diseases and genetic disorders. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. As a result, there is an evident increase in the demand for mRNA manufacturing capacity. Fundamentally, the production of mRNA therapeutics / mRNA vaccines is complex, cost intensive and requires specialized expertise. Therefore, mRNA therapeutic / vaccine developers are actively exploring avenues that enable them to overcome the existing challenges. Amongst other alternatives, outsourcing has emerged as a lucrative option for mRNA therapeutic / vaccine developers. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis and manufacturing services market to witness healthy growth.
Key Market Insights
The “mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022-2035: Distribution by Type of Product (Drug Substances (APIs) and Drug Products (FDFs)), Application Area(s) (mRNA-based Vaccines and mRNA-based Therapeutics), Therapeutic Area(s) (Infectious Diseases, Oncological Disorders and Other Diseases) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts” report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis and manufacturing of research- and GMP-grade mRNA for use in the development of therapeutics and vaccines. The report answers many key questions related to this domain.
mRNA therapeutics and mRNA vaccines have emerged as a promising alternative over conventional treatment approaches owing to their multiple benefits, including shorter development timelines, higher biological efficiency, and versatile delivery platforms at reduced toxicity levels. It is worth highlighting that mRNA therapeutics / mRNA vaccines are anticipated to become a powerful therapeutic modality for the treatment of a variety of refractory diseases, including oncological disorders, metabolic disorders, infectious diseases, cardiovascular disorders, cerebrovascular diseases and other diseases.
The synthesis and manufacturing of mRNA therapeutics and mRNA vaccines is fraught with several challenges as the production of such biomolecules is complex, cost intensive and requires specialized expertise. Scaling up the manufacturing of mRNA is associated with a number of challenges, mostly related to process development, and maintaining purity and stability. Moreover, some of the processes associated with mRNA production, such as purification, involve the use of hazardous solvents / materials. Once manufactured, mRNA therapeutics / mRNA vaccines need to be stored in conditions that do not compromise their stability (thereby, requiring specialized facilities and cold chain transportation). Further, they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases). Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the contract service providers. The COVID-19 pandemic caused a notable surge in the outsourcing activity, with vaccine developers entering into strategic deals with contract service providers to cater to the urgent global demand.
The mRNA synthesis and manufacturing service providers landscape features a mix of over 70 large, mid-sized and small companies, which claim to have the required expertise to offer various services for the synthesis and manufacturing of mRNAs across different scales of operations, worldwide. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market. Recent developments in this segment of the biopharmaceutical industry indicate that the service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for this novel class of biologics.
The success of anti-COVID-19 vaccines has created an enormous need for the consistent supply of these novel vaccines. In the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Moreover, considering the active involvement of big pharma players, as well as new entrants, the development pipeline of mRNA drugs is likely to grow further. The big pharma players have undertaken several initiatives, including strengthening mRNA-based product portfolio, entering into strategic deals and making significant financial investments. Therefore, the growing demand for mRNA as a drug agent, lack of manufacturing capabilities and the need for independent geographical supply chains has prompted the mRNA drug developers to outsource various operations involved in mRNA synthesis to the service providers.
Market Size of the mRNA Synthesis and Manufacturing Services Market
Driven by the rising interest in R&D activities and the demand for mRNA-based products, the future opportunities and growth associated with the mRNA synthesis and manufacturing market is anticipated to witness a noteworthy growth in the foreseen future. Specifically, in terms of type of product, the market is anticipated to be driven by contract manufacturing of mRNA vaccines. In addition to this, presently, close to 70% of the market is captured by players based in North America and Europe.
.webp)
Examples of key players engaged in this domain (which have also been captured in this report) include Aldevron, APExBIO, Biomay, BioNTech, CELLSCRIPT, CureVac, bioSYNTHESIS, eTheRNA, Eurogentec, Jena Biosciences, Moderna, New England Biolabs, Thermo Fisher Scientific and TriLink BioTechnologies.
evolution.
Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
| Report Attribute | Details | |
|
Forecast Period |
2022 – 2035 |
|
|
Type of Product |
Drug Substance (APIs), Drug Products (FDFs) |
|
|
Therapeutic Areas |
Infectious Diseases, Oncological Disorders, Other Diseases | |
|
Key Geographical Regions |
North America, Europe, Asia-Pacific, MENA, Latin America, Rest of the World | |
|
Key Companies Profiled |
Aldevron, APExBIO, Biomay, BioNTech, CELLSCRIPT, CureVac, biosynthesis |
|
|
Customization Scope |
15% Free Customization Option (equivalent to 5 analyst working days) | |
| Excel Data Packs (Complimentary) | Market Landscape Analysis, Company Competitiveness Analysis, Product Competitiveness Analysis, Partnership and Collaboration Analysis, Clinical Trial Analysis, Likely Partners Analysis, Big Pharma Initiative, Market Forecast an Opportunity Analysis | |
Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the mRNA synthesis and contract manufacturing services market over the coming years. We have provided an informed estimates on the likely evolution of the market for the period, 2022-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of product (drug substances (APIs) and drug products (FDFs)), application areas (mRNA-based vaccines and mRNA-based therapeutics), target indications (infectious diseases, oncological disorders and other diseases), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Question 1: What are the factors driving mRNA synthesis and manufacturing market?
Answer: The growing demand for mRNA as a drug agent, lack of manufacturing capabilities and the need for independent geographical supply chains has prompted the mRNA drug developers to outsource various operations involved in mRNA synthesis to the service providers.
Question 2: How many players are providing services for custom synthesis of mRNAs?
Answer: Presently, more than 30 companies claim to offer various custom mRNA synthesis services which include mRNA modification, mRNA purification, manufacturing / scale-up, fill / finish and process development related services.
Question 3: How many players are offering mRNA contract manufacturing services for commercial purposes?
Answer: Close to 70% of the players involved in this domain claim to offer mRNA contract manufacturing services at commercial scale; notable examples include Catalent, Curia, Baxter BioPharma Solutions.
Question 4: How many kits are available in the market for the synthesis of mRNA?
Answer: Currently, more than 95 kits available in the market contain the required components for the synthesis of research grade mRNAs used for various applications.
Question 5: Which geographical segment has the highest growth rate in mRNA synthesis and manufacturing market?
Answer: Asia Pacific is likely to grow at the highest CAGR during the period 2022- 2035.
Question 6: Which segment, in terms of type of product, accounts for the largest mRNA synthesis and manufacturing market share?
Answer: Drug substance (APIs), presently, dominates the mRNA synthesis and manufacturing market with a share of close to 70% in 2022. This is attributable to the rising interest in R&D activities and growing demand for the consistent supply of these novel therapeutic / prophylactic interventions for various disease indications.
Question 7: What is the partnership and collaboration trends in mRNA synthesis and manufacturing domain?
Answer: Currently, manufacturing agreements, fill / finish service agreements and supply agreements are common types of partnerships inked by stakeholders in the mRNA synthesis and manufacturing domain.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. An Overview of mRNA
2.2. Structure of mRNA
2.3. Evolution of mRNA Vaccines
2.4. mRNA Manufacturing Process
2.4.1. Chemical Synthesis of mRNA
2.4.2. In vitro Synthesis of mRNA
2.5. Applications of Chemically / in vitro Synthesized mRNA
2.6. Challenges Associated with mRNA Synthesis
2.7. Commonly Outsourced Manufacturing Operations
2.8. Advantages of Outsourcing Manufacturing Operations
3. MARKET LANDSCAPE: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS
3.1. mRNA Custom Synthesis Service Providers: Overall Market Landscape
3.1.1. Analysis by Year of Establishment
3.1.2. Analysis by Company Size
3.1.3. Analysis by Location of Headquarters
3.1.4. Analysis by Company Size and Location of Headquarters
3.1.5. Analysis by Type of Service(s) Offered
3.1.6. Analysis by Input for Synthesis
3.1.7. Analysis by Structural Modification
3.1.8. Analysis by Type of Purification Method(s)
3.1.9. Analysis by Application Area(s)
3.1.10. Analysis by Scale of Operation
3.1.11. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
3.1.12. mRNA Custom Synthesis Service Providers: Information on mRNA Synthesis / Manufacturing Capacity
4. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
4.1. Key Parameters and Scores
4.2. Methodology
4.3. Competitiveness Analysis: Small Companies
4.4. Competitiveness Analysis: Mid-Sized Companies
4.5. Competitiveness Analysis: Large Companies
5. MARKET LANDSCAPE: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS
5.1. mRNA Contract Manufacturing Service Providers: Overall Market Landscape
5.1.1. Analysis by Year of Establishment
5.1.2. Analysis by Company Size
5.1.3. Analysis by Location of Headquarters
5.1.4. Analysis by Company Size and Location of Headquarters
5.1.5. Analysis by Location of Manufacturing Facility
5.1.6. Analysis by Type of Product(s) Manufactured
5.1.7. Analysis by Type of Service(s) Offered
5.1.8. Analysis by Scale of Operation
6. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
6.1. Methodology
6.2. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
6.3. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
6.4. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific
7. MARKET LANDSCAPE: mRNA SYNTHESIS KIT PROVIDERS
7.1. mRNA Synthesis Kits: Overall Market Landscape
7.1.1. Analysis by Kit Components
7.1.2. Analysis by Type of Enzyme
7.1.3. Analysis by Type of Enzyme Mix Used
7.1.4. Analysis by mRNA Component Modified
7.1.5. Analysis by Yield per Reaction
7.1.6. Analysis by Number of Reactions
7.1.7. Analysis by Reaction Run-Time
7.1.8. Analysis by Price of Kits
7.1.9. Most Active Players: Analysis by Number of mRNA Synthesis Kits Offered
7.2. mRNA Synthesis Kits: Developer Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
8. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS
8.1. Methodology
8.2. Product Competitiveness Analysis: mRNA Synthesis Kits
9. COMPANY PROFILES: mRNA SYNTHESIS AND MANUFACTURING SERVICE PROVIDERS
9.1. Aldevron
9.1.1. Company Overview
9.1.2. mRNA Synthesis Focused Services Portfolio
9.1.3. Recent Developments and Future Outlook
9.2. Biomay
9.2.1. Company Overview
9.2.2. mRNA Synthesis Focused Services Portfolio
9.2.3. Recent Developments and Future Outlook
9.3. Bio-Synthesis
9.3.1. Company Overview
9.3.2. mRNA Synthesis Focused Services Portfolio
9.3.3. Future Outlook
9.4. eTheRNA
9.4.1. Company Overview
9.4.2. mRNA Synthesis Focused Services Portfolio
9.4.3. Recent Developments and Future Outlook
9.5. Eurogentec
9.5.1. Company Overview
9.5.2. mRNA Synthesis Focused Services Portfolio
9.5.3. Recent Developments and Future Outlook
9.6. TriLink BioTechnologies
9.6.1. Company Overview
9.6.2. mRNA Synthesis Focused Services Portfolio
9.6.3. Recent Developments and Future Outlook
10. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS
10.1. APExBIO
10.1.1. Company Overview
10.1.2. mRNA Synthesis Kits Portfolio
10.2. CELLSCRIPT
10.2.1. Company Overview
10.2.2. mRNA Synthesis Kits Portfolio
10.3. Jena Biosciences
10.3.1. Company Overview
10.3.2. mRNA Synthesis Kits Portfolio
10.4. New England Biolabs
10.4.1. Company Overview
10.4.2. mRNA Synthesis Kits Portfolio
10.5. Thermo Fisher Scientific
10.5.1. Company Overview
10.5.2. mRNA Synthesis Kits Portfolio
11. CLINICAL TRIAL ANALYSIS
11.1. Methodology
11.2. mRNA-based Therapeutics / Vaccines: Clinical Trial Analysis
11.2.1. Analysis by Trial Registration Year
11.2.2 Analysis by Trial Status
11.2.3. Analysis by Trial Registration Year and Patients Enrolled
11.2.4. Analysis by Trial Registration Year and Trial Status
11.2.5. Analysis by Trial Phase
11.2.6. Analysis by Target Patient Population
11.2.7. Analysis by Therapeutic Area
11.2.8. Analysis by Type of Sponsor / Collaborator
11.2.9. Most Active Players: Analysis by Number of Trials
11.2.10. Analysis by Region
12. PARTNERSHIP AND COLLABORATIONS
12.1. Partnership Models
12.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
12.1.1. Analysis by Year of Partnership
12.1.2. Analysis by Type of Partnership
12.1.3. Analysis by Year and Type of Partnership
12.1.4. Analysis by Type of Product
12.1.5. Analysis by Type of Partner
12.1.6. Most Active Players: Analysis by Number of Partnerships
12.1.7. Analysis by Local and International Agreements
12.1.8. Analysis by Intercontinental and Intracontinental Agreements
12.1.9. Analysis by Geography
13. LIKELY PARTNERS ANALYSIS
13.1. Methodology
13.2. Likely Partners based in North America
13.2.1 Most Likely Partners based in North America
13.3. Likely Partners based in Europe
13.3.1 Most Likely Partners based in Europe
13.4. Likely Partners based in Asia Pacific and Rest of the World
13.4.1 Most Likely Partners based in Asia Pacific and Rest of the World
14. BIG PHARMA INITIATIVES
14.1. Methodology
14.2. Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
14.3. Competitive Benchmarking of Big Pharma Players
14.3.1. Harvey Ball Analysis
14.3.2. Spider Web Analysis
15. MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions and Forecast Methodology
15.3. Global mRNA Synthesis and Manufacturing Market, 2022-2035
15.3.1. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Type of Product
15.3.1.1. mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), 2022-2035
15.3.1.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), 2022-2035
15.3.2. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Application Area,
15.3.2.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035
15.3.2.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035
15.3.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
15.3.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035
15.3.3.1. mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035
15.3.3.1. mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035
15.3.4. mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2025 and 2035 (USD Billion)
15.3.4.1. mRNA Synthesis and Manufacturing Market in North America, 2022-2035
15.3.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2022-2035
15.3.4.3. mRNA Synthesis and Manufacturing Market in Asia Pacific, 2022-2035
15.3.4.4. mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035
15.3.4.5. mRNA Synthesis and Manufacturing Market in MENA, 2022-2035
15.3.4.6. mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 1.1 Executive Summary: Overall Market Landscape of mRNA Custom Synthesis Service Providers
Figure 1.2 Executive Summary: Overall Market Landscape of mRNA Contract Manufacturing Service Providers
Figure 1.3 Executive Summary: Overall Market Landscape of mRNA Synthesis Kits
Figure 1.4 Executive Summary: Clinical Trial Analysis
Figure 1.5 Executive Summary: Partnership and Collaborations
Figure 1.6 Executive Summary: Likely Partners Analysis
Figure 1.7 Executive Summary: Big Pharma Initiatives
Figure 1.8 Executive Summary: Market Forecast and Opportunity Analysis
Figure 2.1 Structure of mRNA
Figure 2.2 Evolution of mRNA Vaccines
Figure 2.3 Chemical Synthesis of mRNA
Figure 2.4 In vitro Synthesis of mRNA
Figure 3.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Figure 3.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Figure 3.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Figure 3.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Figure 3.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service(s) Offered
Figure 3.6 mRNA Custom Synthesis Service Providers: Distribution by Input for Synthesis
Figure 3.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Figure 3.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method(s)
Figure 3.9 mRNA Custom Synthesis Service Providers: Distribution by Application Area(s)
Figure 3.10 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation(s)
Figure 4.1 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Small Companies)
Figure 4.2 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Small Companies)
Figure 4.3 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Mid-Sized Companies)
Figure 4.4 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Mid-Sized Companies)
Figure 4.5 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Large Companies)
Figure 4.6 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Large Companies)
Figure 5.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 5.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Figure 5.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 5.4 mRNA Contract Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facility
Figure 5.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product(s) Manufactured
Figure 5.7 mRNA Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Figure 5.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation(s)
Figure 6.1 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in North America
Figure 6.3 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in Europe
Figure 6.4 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in Europe
Figure 6.5 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in Asia-Pacific
Figure 6.6 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in Asia-Pacific
Figure 7.1 mRNA Synthesis Kits: Distribution by Kit Components
Figure 7.2 mRNA Synthesis Kits: Distribution by Type of Enzyme(s)
Figure 7.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Figure 7.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Figure 7.5 mRNA Synthesis Kits: Distribution by Yield per Reaction
Figure 7.6 mRNA Synthesis Kits: Distribution by Number of Reactions
Figure 7.7 mRNA Synthesis Kits: Distribution by Reaction Run-Time
Figure 7.8 mRNA Synthesis Kits: Distribution by Price of Kits
Figure 7.9 Most Active Players: Distribution by Number of mRNA Synthesis Kits Offered
Figure 7.10 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Figure 7.11 mRNA Synthesis Kit Providers: Distribution by Company Size
Figure 7.12 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Figure 8.1 Product Competitiveness Analysis: Dot-Plot Representation of mRNA Synthesis Kits
Figure 8.2 Product Competitiveness Analysis: Dot-Plot Representation of Top mRNA Synthesis Kits
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Patient Enrolled
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 11.7 Clinical Trial Analysis: Distribution by Therapeutic Area(s)
Figure 11.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.9 Most Active Players: Analysis by Number of Trials
Figure 11.10 Clinical Trial Analysis: Distribution by Region
Figure 12.1 Partnership and Collaborations: Distribution by Year of Partnership
Figure 12.2 Partnership and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnership and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnership and Collaborations: Distribution by Type of Product(s)
Figure 12.5 Partnership and Collaborations: Distribution by Type of Partner
Figure 12.6 Most Active Players: Analysis by Number of Partnerships
Figure 12.7 Partnership and Collaborations: Distribution by Local and International Agreements
Figure 12.8 Partnership and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 12.9 Partnership and Collaborations: Distribution by Geography
Figure 13.1 Likely Partners Analysis: Likely Partners based in North America
Figure 13.2 Likely Partners Analysis: Most Likely Partners based in North America
Figure 13.3 Likely Partners Analysis: Likely Partners based in Europe
Figure 13.4 Likely Partners Analysis: Most Likely Partners based in Europe
Figure 13.5 Likely Partners Analysis: Likely Partners based in Asia-Pacific and Rest of the World
Figure 13.6 Likely Partners Analysis: Most Likely Partners based in Asia-Pacific and Rest of the World
Figure 14.1 Competitive Benchmarking of Big Pharma Players: Harvey Ball Analysis
Figure 14.2 Competitive Benchmarking of Big Pharma Players: Spider Web Analysis
Figure 15.1 Global mRNA Synthesis and Manufacturing Market, 2022-2035
Figure 15.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2022-2035 (USD Billion)
Figure 15.2 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), 2022-2035 (USD Billion)
Figure 15.3 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), 2022-2035 (USD Billion)
Figure 15.4 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Billion)
Figure 15.5 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035 (USD Billion)
Figure 15.6 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035 (USD Billion)
Figure 15.7 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
Figure 15.8 mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035 (USD Billion)
Figure 15.9 mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035 (USD Billion)
Figure 15.10 mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035 (USD Billion)
Figure 15.11 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 15.12 mRNA Synthesis and Manufacturing Market in North America, 2022-2035 (USD Billion)
Figure 15.13 mRNA Synthesis and Manufacturing Market in Europe, 2022-2035 (USD Billion)
Figure 15.14 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 15.15 mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035 (USD Billion)
Figure 15.16 mRNA Synthesis and Manufacturing Market in MENA, 2022-2035 (USD Billion)
Figure 15.17 mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035, USD Billion
Table 3.1 List of mRNA Custom Synthesis Service Providers
Table 3.2 mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
Table 3.3 mRNA Custom Synthesis Service Providers: Information on Synthesis / Manufacturing Capacity
Table 5.1 List of mRNA Contract Manufacturing Service Providers
Table 7.1 List of mRNA Synthesis Kits
Table 7.2 List of mRNA Synthesis Kits Providers
Table 9.1 Aldevron: mRNA Synthesis Focused Services Portfolio
Table 9.2 Aldevron: Recent Developments and Future Outlook
Table 9.3 Biomay: mRNA Synthesis Focused Services Portfolio
Table 9.4 Biomay: Recent Developments and Future Outlook
Table 9.5 Bio-Synthesis: mRNA Synthesis Focused Services Portfolio
Table 9.6 Bio-Synthesis: Recent Developments and Future Outlook
Table 9.7 eTheRNA: mRNA Synthesis Focused Services Portfolio
Table 9.8 eTheRNA: Recent Developments and Future Outlook
Table 9.9 Eurogentec: mRNA Synthesis Focused Services Portfolio
Table 9.10 Eurogentec: Recent Developments and Future Outlook
Table 9.11 TriLink BioTechnologies: mRNA Synthesis Focused Services Portfolio
Table 9.12 TriLink BioTechnologies: Recent Developments and Future Outlook
Table 10.1 APExBIO: mRNA Synthesis Kits Portfolio
Table 10.2 CELLSCRIPT: mRNA Synthesis Kits Portfolio
Table 10.3 Jena Biosciences: mRNA Synthesis Kits Portfolio
Table 10.4 New England Biolabs: mRNA Synthesis Kits Portfolio
Table 10.5 Thermo Fisher Scientific: mRNA Synthesis Kits Portfolio
Table 11.1 mRNA-based Therapeutics / Vaccines: List of Clinical Trials
Table 12.1 mRNA Synthesis and Manufacturing: List of Partnerships and Collaborations
Table 14.1 Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
Table 16.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
Table 16.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
Table 16.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
Table 16.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service(s) Offered
Table 16.6 mRNA Custom Synthesis Service Providers: Distribution by Input for Synthesis
Table 16.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
Table 16.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method(s)
Table 16.9 mRNA Custom Synthesis Service Providers: Distribution by Application Area(s)
Table 16.10 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation(s)
Table 16.11 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 16.12 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
Table 16.13 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Table 16.14 mRNA Contract Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.15 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facility
Table 16.16 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product(s) Manufactured
Table 16.17 mRNA Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Table 16.18 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation(s)
Table 16.19 mRNA Synthesis Kits: Distribution by Kit Components
Table 16.20 mRNA Synthesis Kits: Distribution by Type of Enzyme(s)
Table 16.21 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
Table 16.22 mRNA Synthesis Kits: Distribution by mRNA Component Modified
Table 16.23 mRNA Synthesis Kits: Distribution by Yield per Reaction
Table 16.24 mRNA Synthesis Kits: Distribution by Number of Reactions
Table 16.25 mRNA Synthesis Kits: Distribution by Reaction Run-Time
Table 16.26 mRNA Synthesis Kits: Distribution by Price of Kits
Table 16.27 Most Active Players: Distribution by Number of mRNA Synthesis Kits Offered
Table 16.28 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
Table 16.29 mRNA Synthesis Kit Providers: Distribution by Company Size
Table 16.30 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
Table 16.32 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 16.33 Clinical Trial Analysis: Distribution by Trial Status
Table 16.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Patient Enrolled
Table 16.35 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 16.36 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.37 Clinical Trial Analysis: Distribution by Target Patient Population
Table 16.38 Clinical Trial Analysis: Distribution by Therapeutic Area(s)
Table 16.39 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.40 Most Active Players: Distribution by Number of Trials
Table 16.41 Clinical Trial Analysis: Distribution by Region
Table 16.42 Partnership and Collaborations: Distribution by Year of Partnership
Table 16.43 Partnership and Collaborations: Distribution by Type of Partnership
Table 16.44 Partnership and Collaborations: Distribution by Year and Type of Partnership
Table 16.45 Partnership and Collaborations: Distribution by Type of Product(s)
Table 16.46 Partnership and Collaborations: Distribution by Type of Partner
Table 16.47 Most Active Players: Distribution by Number of Partnerships
Table 16.48 Partnership and Collaborations: Distribution by Local and International Agreements
Table 16.49 Partnership and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 16.50 Partnership and Collaborations: Distribution by Geography
Table 16.51 Global mRNA Synthesis and Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.52 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2022- 2035 (USD Billion)
Table 16.53 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs) Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.54 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs) Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.55 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Billion)
Table 16.56 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.57 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.58 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
Table 16.59 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.60 mRNA Synthesis and Manufacturing Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.61 mRNA Synthesis and Manufacturing Market for Other Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.62 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 16.63 mRNA Synthesis and Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.64 mRNA Synthesis and Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.65 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.66 mRNA Synthesis and Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.67 mRNA Synthesis and Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 16.68 mRNA Synthesis and Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES